Hillstar Bio, a Boston-based biotechnology innovator, launched from stealth today with $67 million in Series A funding. Investors including Droia Ventures, Frazier Life Sciences and Novo Holdings A/S participated in the round that will allow the company to advance its lead therapeutic candidate into clinical trials.
Hillstar Bio specializes in treating autoimmune diseases through precision immunotherapies. The company’s treatment method selectively depletes pathogenic cells while preserving healthy ones. The company will initially focus on treating axial spondyloarthritis before expanding to tackle other immune and inflammatory conditions.
Its goal is to provide patients with lasting relief and restore their immune systems to a healthy and balanced state. The company’s lead program specifically targets TRBV9+ T cells. With the fresh capital, Hillstar Bio plans to put this program through clinical proof-of-concept studies in 2026 and continue progressing its broader pipeline.
